Description
The world’s only searchable, sortable database of regenerative medicine (RM) investors that is updated on a daily basis.
Regenerative medicine (RM) companies raised $4.8 billion in the first half of 2019 and $5.1 billion in the second half of 2019, bringing funding flowing into RM companies to an impressive $9.9 billion in 2019. In 2020, this number is estimated to reach to $11.4 billion, with numerous regenerative medicines products being explored for their use in the treatment and prevention of COVID-19.
Regenerative medicine companies are defined as those involved with cell therapies, gene therapies, exosomes, tissue engineering, biomaterials, or other related therapies involving the use of human cells and tissues.
Regenerative medicine industry investors include:
- Venture Capital Groups
- Private Equity Firms
- Hedge Funds
- Endowment Funds
- Angel Investors (for example, Tony Robbins, Bill Maris, Peter Diamandis and others)
Database of Regenerative Medicine (RM) Investors
This database reveals the identity and investment behaviors of 72 investors who specialize in companies commercializing regenerative medicine (RM) and advanced therapy (AT) products.
It was originally developed in-house for our own purposes, but we had clients repeatedly requesting access to it. Because it is an essential resource within our company, we are confident it will be a valuable resource for you too.
This comprehensive global database includes:
- Investor Identity (Individual or Company Name)
- Type of Investor
- Year Founded
- City/State
- Country
- Company Website
- Description of the Investor
- Companies Funded
- Phone Number
- Email Address
Use this database to identify potential targets if you plan to pursue:
- Seed rounds
- Venture rounds
- Private placements
- Loans and convertible debt
- Any activity requiring external funding
It can also be used to strengthen your network by meeting the RM industry’s most influential investors.
Imagine being immediately informed about investor profiles and preferences, without sacrificing weeks of unnecessary research or missing critical opportunities.
For a limited-time, you can claim it for 40% off. Act now and your product will be delivered instantly as an Excel download.
